InnoCare Pharma (STU:33C) Current Deferred Revenue: €0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:33C InnoCare Pharma Ltd STU:33C
78 GF Score
Price €1.51
GF Value €2.29
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma Current Deferred Revenue?

InnoCare Pharma STU:33C -3.21% 78 Current Deferred Revenue is €0.0 Mil as of Dec. 2025. GuruFocus rates STU:33C with a GF Score™ of 78/100 and a GF Value™ of €2.29 (Possible Value Trap). The stock has 7 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

InnoCare Pharma's current deferred revenue for the quarter that ended in Dec. 2025 was €0.0 Mil.

InnoCare Pharma Current Deferred Revenue Related Terms

InnoCare Pharma Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for InnoCare Pharma's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma Current Deferred Revenue Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

InnoCare Pharma Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:33C
78GF Score
InnoCare Pharma Ltd STU:33C
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €0.0 Mil mean?
InnoCare Pharma (STU:33C) has a Current Deferred Revenue of €0.0 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on InnoCare Pharma and its competitors.
Is InnoCare Pharma's Current Deferred Revenue too high?
InnoCare Pharma's current Current Deferred Revenue is €0.0 Mil. Overall, InnoCare Pharma has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Current Deferred Revenue compare to VRTX and REGN?
InnoCare Pharma's Current Deferred Revenue of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on InnoCare Pharma and its competitors. InnoCare Pharma's current Current Deferred Revenue is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Pharma (STU:33C) is currently considered Possible Value Trap. The stock's GF Value™ is €2.29, compared to a current price of €1.51 — trading 34.1% below its estimated fair value. The current Current Deferred Revenue is €0.0 Mil. InnoCare Pharma's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For InnoCare Pharma (STU:33C), the current Current Deferred Revenue is €0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCare Pharma (STU:33C) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of €1.51 is trading 34.1% below its estimated GF Value™ of €2.29. GuruFocus considers InnoCare Pharma to be Possible Value Trap.

Key valuation signals for STU:33C:

  • Current Deferred Revenue: €0.0 Mil
  • GF Value™: €2.29 vs. price of €1.51 (34.1% below fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the STU:33C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCare Pharma Business Description

Other Exchanges 09969:Hong Kong688428:China
Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
78GF Score

Get the complete analysis for STU:33C

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price
€2.29
GF Value